Taisho, others assessing Actis, Sequoia India investee Paras Pharma
Japanese pharma major Taisho Pharmaceutical Co. Ltd., as well as at least one other leading non-Indian drug firm, is conducting due diligence on Actis Capital and Sequoia Capital investee Paras Pharmaceuticals, in a competitive exit process that could fetch up to $800 million.
Paras specializes in both health and personal care products, from over-the-counter remedies to toiletries. Taisho had previously sought an Indian government FDI approval to expand into India, and may look...
More on South Asia
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.